EU door opens for generic version of AIDS medicine Truvada

July 26, 2018
European patents expired on July 25 for Truvada, allowing EU authorities to clear the way for cheaper generics to enter the market

Patient associations on Thursday lauded an EU decision to allow the sale of generic versions of Truvada, an anti-retroviral medicine used by those diagnosed HIV-positive, the virus causing AIDS.

"This decision is historic ... ending an inherent monopoly," said the Coalition PLUS and Aides associations in a statement.

Truvada, made by US lab Gilead, is one of the most widely used medicines to treat patients with the HIV virus and was to date the only one enjoying Europe-wide clearance for patients deemed high infection risk.

But European patents on the medicine expired on Wednesday, providing a window of opportunity for generics.

In some European states, however, Gilead retains a monopoly owing to a complementary certificate of protection (CCP) which extends the period of exclusivity afforded a product.

Four rival labs—Teva, Accord Healthcare, Lupin and Mylan—had sought to have that overturned in the courts in Britain—which called on the European Court of Justice to make a ruling.

The ruling, which came down on Wednesday, highlighted the fact that Truvada contains two active substances—emtricitabine and tenofovir disoproxil—but only the second of the two is explicitly mentioned in the basic patent.

The judge argued that as a result, the conditions for a CCP were not met.

French authorities had reached a similar conclusion last September in rejecting a Gilead demand to prevent commercialisation of a Truvada generic developed by France's Mylan laboratory.

Five generics are now available in France, resulting in a significant price drop—around 160 euros ($190) a bottle compared with more than 400 euros for Truvada under its monopoly.

The Aides association said the appearance of generic options had resulted in more than 760 million euros of savings, adding that Europe-wide the benefit could run into the billions while offering heightened protection against infection for thousands of people.

Explore further: Europe's medicine watchdog okays preventive AIDS pill

Related Stories

Europe's medicine watchdog okays preventive AIDS pill

July 22, 2016
Europe's medicines watchdog said Friday it has recommended the licencing of the first-ever AIDS prevention pill for the European Union.

US delays decision on first drug to prevent HIV

June 9, 2012
(AP) — Drugmaker Gilead Sciences Inc. says federal health regulators have delayed a decision on whether to approve its drug Truvada as the first pill that prevents HIV infection.

French charity attacks Gilead patent for hepatitis drug

February 10, 2015
French charity Medecins du Monde (MdM) on Tuesday said it was contesting a European patent awarded to a hepatitis drug made by US firm Gilead Sciences, arguing the treatment was too costly.

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

AIDS fight enters new phase with prevention pill

May 11, 2012
(AP) -- Condoms and other safe-sex practices have accomplished only so much. Now the 30-year battle against AIDS is on the verge of a radical new phase, with the government expected to endorse a once-a-day pill to prevent ...

AIDS prevention pill study halted; no benefit seen

April 18, 2011
Researchers are stopping a study that tests a daily pill to prevent infection with the AIDS virus in thousands of African women because partial results show no signs that the drug is doing any good.

Recommended for you

Long-acting injectable implant shows promise for HIV treatment and prevention

October 9, 2018
A persistent challenge in HIV/AIDS treatment and prevention is medication adherence – getting patients to take their medication as required to get the best results.

Scientists develop rapid test for diagnosing tuberculosis in people with HIV

October 8, 2018
An international team that includes Rutgers scientists has made significant progress in developing a urine diagnostic test that can quickly, easily and inexpensively identify tuberculosis infection in people also infected ...

Researchers uncover new role of TIP60 protein in controlling tumour formation

October 8, 2018
Scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have discovered a new molecular pathway that controls colorectal cancer development, and their exciting ...

Combination therapy targets latent reservoir of HIV

October 3, 2018
With more than 35 million people worldwide living with the virus and nearly 2 million new cases each year, the human immunodeficiency virus (HIV) remains a major global epidemic. Existing antiretroviral drugs do not cure ...

Anti-integrin therapy effect on intestinal immune system in HIV-infected patients

October 3, 2018
In a study published today in Science Translational Medicine, Mount Sinai researchers describe for the first time a mechanism that may shrink collections of immune cells in the gastrointestinal (GI) tract, called lymphoid ...

No 'reservoir': Detectable HIV-1 in treated human liver cells found to be inert

October 1, 2018
In a proof-of-principle study, researchers at Johns Hopkins report that a certain liver immune cell called a macrophage contains only defective or inert HIV-1 copies, and aren't likely to restart infection on their own in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.